• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Trade Cautiously With Sorrento Therapeutics

Short-term traders may want to nail down profits and be careful in their trading strategy with this name.
By BRUCE KAMICH
Aug 11, 2020 | 11:18 AM EDT
Stocks quotes in this article: NVAX, SRNE

In a raging bull market, stocks that are in motion tend to stay in motion, Cramer told viewers of Monday's Mad Money program, and just like Newton's first law, stocks that are heading higher tend to keep heading higher.

Cramer said shares of Novavax (NVAX) continue to rocket higher on no news. The stock has soared 4,385% so far this year, despite the fact that this company has never successfully brought a vaccine to market. Then there's Sorrento Therapeutics Inc. (SRNE) , the early-stage biotech that's up 537% over the past six months on the promise of its COVID-19 test.

Let's check out the charts of SRNE.

In this daily Japanese candlestick chart of SRNE, below, we can see the explosive upside move that appears to have come out of nowhere. Prices were trading sideways around $2 -- and then in the middle of May, we can see a gap to the upside. Prices spiked higher for just two days and then slowly gave back most of the gains over the next several days.

Another round of buying came in early June and pushed prices briefly up over $18. The two-day candle pattern now looks like a harami reversal, but will need bearish confirmation tomorrow. With huge gains for early buyers, the odds of heavy profit taking are higher. SRNE is extended above the rising 50-day moving average line and the rising 200-day moving average line.

The daily On-Balance-Volume (OBV) line shows a lot of aggressive buying since May, but it may have made a short-term peak. The 12-day price momentum study does not show us a bearish divergence yet, but we may have seen a peak in upside acceleration.

In this weekly bar chart of SRNE, below, we can see a different perspective on the price action. Here we can see that investors with vision could have bought all the shares of SRNE they would have wanted around $2. Trading volume was nearly invisible until recently and prices are up nearly 10-fold. The slope of the 40-week moving average line is positive. The OBV line is strong and the Moving Average Convergence Divergence oscillator is bullish.

In this Point and Figure chart of SRNE, below, we used daily price data. Prices have reached an exceeded the projected target of $15.87.

Bottom line strategy: A possible harami reversal on the candlestick chart and the first sign that trading volume could be increasing on a down day (a peak in the OBV line) suggest that short-term traders may want to nail down profits and trade more cautiously.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Investing | Technical Analysis | Biotechnology | Health Care Equipment & Services | Mad Money | Coronavirus

More from Investing

Corrective Action Produces Fading Confidence and Technical Damage

James "Rev Shark" DePorre
Feb 26, 2021 5:08 PM EST

It's dangerous to have too much exposure now, but the potential for a good recovery is there once interest rate issues are digested.

I'm Intrigued by the Recent Pullback in Aurora Mobile

Timothy Collins
Feb 26, 2021 3:30 PM EST

While the Chinese company is still not profitable, it is cash flow positive.

Salesforce Gets a Quant Downgrade on Top of Weakening Charts

Bruce Kamich
Feb 26, 2021 12:50 PM EST

Here's what investors and traders need to think about.

My Preference Right Now Is to Buy Pre-Deals

Timothy Collins
Feb 26, 2021 12:36 PM EST

I've added a few names that I see as a great risk-reward because of the limited downside.

I've Been a Buyer Friday, Making Partial Buys Like I Always Do

James "Rev Shark" DePorre
Feb 26, 2021 12:07 PM EST

It's premature to predict that a low has been made, but plenty of stocks are quite washed-out already and are starting to find support.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:32 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Navigating a Market Correction
  • 11:29 AM EST GARY BERMAN

    Where Does the Nasdaq Go From Here?

    Where does the Nasdaq Composite (CCMP) index go fr...
  • 12:31 PM EST GARY BERMAN

    Has the Short-Term Top Come for the XLF/Banks?

    The has triggered a long-term overbought signal ...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login